Pembrolizumab + Olaparib for Bile Duct Cancer
Recruiting in Palo Alto (17 mi)
+2 other locations
Overseen ByJohn Marshall, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Georgetown University
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?This trial tests a combination of two drugs, olaparib and pembrolizumab, in patients with advanced bile duct cancer who haven't responded to standard treatment. Olaparib makes it harder for cancer cells to repair themselves, while pembrolizumab helps the immune system attack the cancer. The goal is to see if this combination can improve treatment response rates and extend patient survival.
Eligibility Criteria
Participant Groups
1Treatment groups
Experimental Treatment
Group I: ExperimentalExperimental Treatment2 Interventions
Pembrolizumab Q3W, IV infusion (day 1 of each 3 week cycle)
Olaparib bid, Oral tablet continuously
Olaparib is already approved in European Union, United States for the following indications:
๐ช๐บ Approved in European Union as Lynparza for:
- Breast cancer
- Ovarian cancer
- Fallopian tube cancer
- Peritoneal cancer
- Pancreatic cancer
- Prostate cancer
- Endometrial cancer
๐บ๐ธ Approved in United States as Lynparza for:
- Ovarian, fallopian tube, and primary peritoneal cancer
- Breast cancer
- Prostate cancer
- Pancreatic cancer
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Lombardi Comprehensive Cancer Center, Georgetown UniversityWashington, United States
Lombardi Cancer Center at Georgetown UniversityWashington, United States
Jane GallagherWashington, United States
Loading ...
Who is running the clinical trial?
Georgetown UniversityLead Sponsor